中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于合肥立方制药股份有限公司 致：合肥立方制药股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受合肥立方制药股份有限 公司（以下简称"公司"）的委托，指派本所律师列席公司于 2025 年 8 月 29 日下 午 14 时 30 分在安徽省合肥市文曲路 446 号科研综合楼五楼会议中心召开的 2025 年第一次临时股东大会（以下称"本次股东大会"），并依据《中华人民共和国公 司法》等中国法律、法规和相关规范性文件（以下称"中国法律法规"）及《合肥 立方制药股份有限公司章程》（以下称"公司章程"）的规定，就本次股东大会的 召集和召开程序、出席会议人员资格、召集人资格、会议表决程序和表决结果等 事宜（以下称"程序事宜"）出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东大会的文件， 包括但不限于公司第五届董事会第二十二次会议决议以及根据上述决议内容刊 登的公告、本次股东大会的通知、议案和决议等，同时听取 ...

证券代码：003020 证券简称：立方制药 公告编号：2025-065 合肥立方制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开和出席情况 （1）现场会议时间：2025 年 8 月 29 日（星期五）下午 14:30。 其中：通过现场投票的股东及股东代理人 17 名（代表 18 名股东），代表股 份 108,670,270 股，占公司有表决权股份总数的 57.1401%。通过网络投票的股东 （2）中小股东出席会议情况 通过现场和网络投票的中小股东及代理人 129 名，代表股份 12,107,053 股， 占公司有表决权股份总数的 6.3660%。 其中：通过现场投票的中小股东及代理人 6 名，代表股份 2,777,149 股，占 公司有表决权股份总数的 1.4603%。 （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为：2025 年 8 月 29 日 9:15—9:25、9:30—11:30、13:00—15:00；通过深圳证券交易所互联 网投票系统投票的时间为：2025 年 8 月 29 日 9:15-15 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于合肥立方制药股份有限公司 2025年第一次临时股东大会的法律意见书 致：合肥立方制药股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受合肥立方制药股份有限 公司（以下简称"公司"）的委托，指派本所律师列席公司于 2025 年 8 月 29 日下 午14时30分在安徽省合肥市文曲路446号科研综合楼五楼会议中心召开的2025 年第一次临时股东大会（以下称"本次股东大会"），并依据《中华人民共和国公 司法》等中国法律、法规和相关规范性文件（以下称"中国法律法规"）及《合肥 立方制药股份有限公司章程》（以下称"公司章程"）的规定，就本次股东大会的 召集和召开程序、出席会议人员资格、召集人资格、会议表决程序和表决结果等 事宜（以下称"程序事宜"）出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东大会的文件， 包括但不限于公司第五届董事会第二十二次会议决议以及根据上述决议内容刊 登的公告、本次股东大会的 ...

（文章来源：每日经济新闻） 每经AI快讯，8月29日，A股化学制药板块触底反弹，向日葵涨20%涨停，多瑞医药涨超13%，华海药 业、同和药业均涨9%，华纳药厂、立方制药等涨。 ...

Core Viewpoint - The innovative pharmaceutical stocks experienced a significant rebound, with Huahai Pharmaceutical and Kangchen Pharmaceutical both hitting the daily limit up, indicating strong market interest and investor confidence in the sector [1] Industry Summary - The National Medical Products Administration of China reported that the country's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs currently under research [1] - Since the beginning of the 14th Five-Year Plan, a total of 387 pediatric drugs and 147 rare disease drugs have been approved for market, effectively addressing the medication needs of key populations [1] Company Summary - Huahai Pharmaceutical and Kangchen Pharmaceutical both reached the daily limit up, reflecting positive market sentiment towards their stock performance [1] - Other companies such as Puris, Duolai Pharmaceutical, Haoyuan Pharmaceutical, Huana Pharmaceutical, Medisi, Lifang Pharmaceutical, and Guangshengtang also saw stock increases, with some rising over 5% [1]

Core Insights - The report highlights the rapid development of the AI industry in China, driven by the government's "Artificial Intelligence+" initiative, which sets ambitious goals for AI integration across various sectors by 2035 [5] - The chemical raw materials sector is experiencing growth due to increased demand for AI servers, with a focus on high-frequency and high-speed copper-clad laminate materials [6] - The pharmaceutical company Lifan Pharmaceutical is set to launch a new ADHD treatment, with significant increases in R&D investment [7] - Runfeng Co. has reported substantial growth in operating performance, driven by global operations [8] - Times New Materials has seen a rise in revenue and profit, with new materials becoming a key growth area [12] - Guangqi Technology is experiencing rapid growth in its metamaterials business, with steady progress in production base construction [15] - Changrun Co. has improved profit margins significantly, driven by product diversification and strong overseas contributions [17] - Longcheng Securities has shown comprehensive improvement in performance, with investment business driving growth [24] - Baofeng Energy's projects in Inner Mongolia are contributing to revenue growth, with ongoing projects being actively advanced [28] Industry Commentary - The "Artificial Intelligence+" policy aims for deep integration of AI in six key areas by 2027, with a target of over 90% application penetration by 2030 [5] - The new materials sector is benefiting from the rising demand for AI servers, with the global AI server market projected to grow significantly [6] - The pharmaceutical industry is seeing innovation with new drug approvals and increased R&D spending, particularly in ADHD treatments [7] - The agricultural chemicals market is recovering, with a focus on high-margin products and global market expansion [10] - The wind power sector is expected to maintain high growth, driven by new installations and international collaborations [12] - The metamaterials market is expanding, with increasing demand for advanced materials in various applications [15] - The automotive parts industry is adapting to market changes, with a focus on product diversification and international production capabilities [17] Company-Specific Insights - Lifan Pharmaceutical's revenue for H1 2025 was 732 million yuan, with a net profit of 90.23 million yuan, reflecting a 16.53% increase [7] - Runfeng Co. anticipates revenues of 1.796 billion yuan in 2025, with net profits projected to reach 198 million yuan [9] - Times New Materials reported H1 revenue of 9.256 billion yuan, with a net profit of 303 million yuan, indicating a 36.66% increase [12] - Guangqi Technology's H1 revenue was 943 million yuan, with a net profit of 386 million yuan, showing a 6.75% increase [15] - Changrun Co. achieved H1 revenue of 1.4 billion yuan, with a net profit of 107 million yuan, despite a slight decline in revenue [17] - Longcheng Securities reported H1 revenue of 2.859 billion yuan, with a net profit of 1.385 billion yuan, reflecting a 91.92% increase [26] - Baofeng Energy's H1 revenue reached 22.82 billion yuan, with a 35% year-on-year increase [28]

- The report does not contain any quantitative models or factors for analysis

Core Viewpoint - The company reported a decline in revenue for the first half of 2025, but achieved a significant increase in net profit, indicating a mixed performance with strong growth in certain product lines [1][2]. Financial Performance - The company achieved operating revenue of 732 million yuan in the first half of 2025, a year-on-year decrease of 4.80% [1]. - The pharmaceutical industrial revenue was 667.52 million yuan, down 4.74% year-on-year, while retail revenue remained stable at 56.45 million yuan [1]. - The net profit attributable to shareholders was 90.23 million yuan, an increase of 16.53% year-on-year, with a basic earnings per share of 0.47 yuan [1]. - R&D investment reached 58.75 million yuan, up 49.22% year-on-year [1]. Product Performance - Sales of key industrial products showed steady growth, particularly for sustained-release formulations like nifedipine controlled-release tablets and Ge Guo Tong Luo capsules [2]. - The launch of hydromorphone sustained-release tablets achieved over 100 million yuan in sales in its first full year, maintaining good growth in the first half of the year [2]. - New products such as paliperidone sustained-release tablets and ophthalmic formulations were approved, expanding the product portfolio [2]. Technological and Industrial Advantages - The company has a strong industrialization advantage with its core osmotic pump controlled-release technology, being one of the few designated manufacturers of first-class psychotropic and narcotic drugs in China [3]. - The technology platform includes formulation technology, evaluation technology, engineering technology, and key equipment technology, enhancing product development capabilities [3]. - The company has a diverse product lineup, including various sustained-release formulations and traditional Chinese medicine products [3]. Future Outlook - Revenue projections for 2025 to 2027 are 1.796 billion yuan, 2.239 billion yuan, and 2.766 billion yuan, respectively, with net profits expected to reach 198 million yuan, 257 million yuan, and 341 million yuan [4]. - The competitive landscape for hydromorphone and methylphenidate is favorable, with high policy and technical barriers, and new product development is underway [4].

立方制药今日跌停，全天换手率13.82%，成交额6.42亿元，振幅12.63%。龙虎榜数据显示，机构净买入 1530.00万元，营业部席位合计净卖出6150.69万元。 深交所公开信息显示，当日该股因日跌幅偏离值达-8.09%上榜，机构专用席位净买入1530.00万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.61亿元，其中，买入成交额为5730.25 万元，卖出成交额为1.04亿元，合计净卖出4620.69万元。 具体来看，今日上榜的营业部中，共有4家机构专用席位现身，即买一、买二、买四、买五、卖五，合 计买入金额4452.03万元，卖出金额2922.03万元，合计净买入1530.00万元。 近半年该股累计上榜龙虎榜8次，上榜次日股价平均跌0.50%，上榜后5日平均跌3.44%。 资金流向方面，今日该股主力资金净流出1.19亿元，其中，特大单净流出4471.76万元，大单资金净流出 7402.64万元。近5日主力资金净流出1.18亿元。（数据宝） 立方制药8月27日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688658 | 悦康药业 | 26.45 | -16.82% | 24.43万 | 6.87亿 | | 300436 | 广生堂 | 124.55 | -10.32% | 20.26万 | 26.49亿 | | 003020 | 立方制药 | 32.31 | -10.00% | 19.03万 | 6.42 亿 | | 002653 | 海思科 | 55.48 | -8.30% | 8.63万 | 4.90亿 | | 688553 | 汇宇制药 | 24.89 | -7.99% | 23.26万 | 5.80 Z | | 300204 | 舒泰神 | 53.00 | -6.53% | 34.19万 | 18.75亿 | | 002332 | 仙琚制药 | 10.75 | -6.52% | 64.73万 | 7.19亿 | | 002020 | 京新药业 | 19.09 | -6.51% | 30.01万 | 5.92亿 | | 688356 | 键 ...